Reference : Real-life practice study of the clinical outcome and cost-effectiveness of photodynam...
Scientific journals : Article
Human health sciences : Dermatology
Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma
Annemans, Lieven mailto [Universitair Ziekenhuis Gent - UZ > > > >]
Caekelbergh, Karin [IMS Health, Brussels > > > >]
Roelandts, Rik [Universitair Ziekenhuis Leuven > > > >]
Boonen, Hugo [H. Hart, Mol > > > >]
Leys, Christophe [Centre Hospitalier Universitaire de Liège - CHU > > Dermatologie >]
Nikkels, Arjen mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatologie >]
van Den Haute, V. [Clinique 2 Alice, Uccle > > > >]
van Quickenborne, L. [A.Z. Sint-Lucas Ghent > > > >]
Verhaeghe, Evelien [Universitair Ziekenhuis Gent - UZ > > > >]
Leroy, Bernard [Cliniques Universitaires Saint-Luc (Bruxelles) > > > >]
European Journal of Dermatology
John Libbey Eurotext
Yes (verified by ORBi)
[en] actinic keratosis ; basal cell carcinoma ; methyl aminolevulinate ; photodynamic therapy ; pharmacoeconomics ; MAL PDT
[fr] kératose actinique ; thérapie photodynamique
[en] Photodynamic therapy with methyl aminolevulinate (MAL-PDT) is a non-invasive therapy for superficial and nodular basal cell carcinoma (BCC). We performed an open-label trial to evaluate efficacy, safety, tolerability and cosmetic outcome of MAL-PDT in selected patients with superficial and nodular BCCs. Ninety-four superficial and 24 nodular BCCs in 69 patients were treated with 2 to 8 MAL-PDT sessions. Efficacy, safety, tolerability and cosmetic outcome were evaluated at months 1, 3, 6 and 12 after the last MAL-PDT treatment and then every 3 months. One patient discontinued the study for reasons unrelated to study procedures. Complete clinical regression was detected in 84/94 (89.4%) superficial BCCs, and 12/23 (52.2%) nodular BCCs one month after 2 MAL-PDT sessions. No further clinical improvement was observed in either superficial or nodular BCCs with treatment continuation up to a maximum of 8 MAL-PDT sessions. Adverse effects were limited to mild local skin reactions, and cosmetic outcome was rated as excellent or good. Recurrence was observed in 2/84 (2.4%) successfully treated superficial BCCs at 6 and 12 months after treatment discontinuation. Based on the efficacy, tolerability, cosmetic outcome and recurrence rate, our results support the use of MAL-PDT for treatment of superficial BCC and for selected cases of nodular BCC.

File(s) associated to this reference

Fulltext file(s):

Restricted access
2008_REALLIFEPDTEurJDerm2.pdfNo commentaryPublisher postprint161.4 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.